NuCana Secures Key Patent for NUC-7738 in China

Nucana ( (NCNA) ) just unveiled an update.

On November 5, 2025, NuCana announced the issuance of a new patent by the China National Intellectual Property Administration for NUC-7738’s composition of matter. This patent strengthens NuCana’s global intellectual property strategy and supports opportunities for innovative cancer therapies in China. The patent is a key milestone in the company’s efforts to address unmet needs in cancer treatment, particularly in combination with pembrolizumab for melanoma patients.

Spark’s Take on NCNA Stock

According to Spark, TipRanks’ AI Analyst, NCNA is a Underperform.

Nucana’s overall score is primarily impacted by its financial instability and negative valuation metrics. The significant lack of revenue generation and operational losses are major concerns. Despite showing strong cash management and low leverage, the company’s technical indicators suggest a bearish trend, further weighing down the score. The poor valuation metrics, such as a negative P/E ratio, are offset by potential speculative interest due to the low stock price. The absence of notable earnings call insights or corporate events means these factors did not influence the score.

To see Spark’s full report on NCNA stock, click here.

More about Nucana

NuCana is a clinical-stage biopharmaceutical company focused on improving treatment outcomes for cancer patients by using its ProTide technology to transform widely prescribed chemotherapy agents into more effective and safer medicines. The company’s pipeline includes NUC-7738 and NUC-3373, which are designed to overcome the limitations of traditional nucleoside analogs and enhance anti-cancer effects.

Average Trading Volume: 526,098

Technical Sentiment Signal: Sell

Current Market Cap: $6.93M

Find detailed analytics on NCNA stock on TipRanks’ Stock Analysis page.